New hope in the fight against HIV? The European Union gives the green light to a new preventive treatment

New hope in the fight against HIV. Lenacapavir, a new preventive treatment, could, according to a study, be a solution to reduce the risk of HIV infection. The European Medicines Agency (EMA) approved this week the approval of this new treatment, which requires two injections per year.

"The initiative is good. Afterwards, the six-month thing, I'm not sure that in terms of regularity, there are many people who do it," a passerby told BFMTV.

"It's cool that it's happening, but I don't think I would have had any use for it, that's why I won't be taking it," adds another local resident.

This treatment is intended for people who do not have HIV and reduces the risk of contamination by almost 100% by targeting infected cells in order to limit the spread of the virus in the body.

For associations fighting the virus, this drug offers hope. "The concern now is that people, young and old, are not protecting themselves sufficiently," Florence Thune, executive director of Sidaction, told BFMTV.

"We hope that with a longer duration of effectiveness, more people will turn to this type of tool," she adds.

Various researchers hope that this treatment will be available on the market by 2027. In 2024, 1.3 million people were infected with HIV.